Sign In
Buy GLPG
$27.38
+0.0650 (+0.238%)
At Close: Jun 03, 2026
Galapagos (NASDAQ:GLPG) Sets New 12-Month Low at $47.96
05:18pm, Tuesday, 23'rd Nov 2021 Dakota Financial News
Galapagos NV (NASDAQ:GLPG) reached a new 52-week low on Tuesday . The stock traded as low as $47.96 and last traded at $47.96, with a volume of 3144 shares. The stock had previously closed at $49.30. GLPG has been the topic of several research analyst reports. Royal Bank of Canada lifted their price objective on []
Galapagos NV: Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
09:05pm, Monday, 22'nd Nov 2021 FinanzNachrichten
Mechelen, Belgium; 22 November 2021, 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease
09:01pm, Monday, 22'nd Nov 2021 Intrado Digital Media
Mechelen, Belgium; 22 November 2021 , 22. 01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD).
Bvf Inc Buys Galapagos NV, Amarin Corp PLC, Aadi Bioscience Inc, Sells Merus NV, argenx SE, ...
02:38am, Wednesday, 17'th Nov 2021 GuruFocus
Related Stocks: AMRN , KYMR , LXRX , CRNX , RAIN , VSTM , GLPG , AADI , TYRA , PNT , ALPN , ELEV , MRUS , RACA , FBRX , IMVT , CNTA ,
Sio Capital Management, LLC Buys Galapagos NV, Cigna Corp, Merck Inc, Sells Hill-Rom Holdings ...
09:38pm, Tuesday, 16'th Nov 2021 GuruFocus
Related Stocks: CI , CAH , UHS , HLF , UTHR , GLPG , MRK , RCOR , GILD , LPTX , PTGX , HRC , AMGN , AFMD , CHRS , SYNH , CHAQ.U ,
Aquilo Capital Management, LLC Buys Arvinas Inc, Dicerna Pharmaceuticals Inc, Regenxbio Inc, ...
07:38pm, Tuesday, 16'th Nov 2021 GuruFocus
Related Stocks: DRNA , RGNX , ARWR , AMYT , ARVN , NGM , HARP , GLPG ,
Galapagos NV (NASDAQ:GLPG) Given Consensus Recommendation of “Hold” by Brokerages
06:30am, Tuesday, 16'th Nov 2021 Transcript Daily
Shares of Galapagos NV (NASDAQ:GLPG) have earned a consensus rating of “Hold” from the fourteen research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating on the company. The average […]
EcoR1 Capital, LLC Buys Galapagos NV, Arcus Biosciences Inc, Protagonist Therapeutics Inc, ...
11:38pm, Monday, 15'th Nov 2021 GuruFocus
Related Stocks: RCUS , GRTS , RNA , NRIX , DSGN , ODT , GLPG , PTGX , TNGX , ERAS , IMVT , BLUE , TBIO , KYMR , ARVN , BCEL , KDNY , ZNTL ,
Galapagos NV: Jyseleca?(filgotinib) approved in the European Union for the treatment of ulcerative colitis
03:53pm, Monday, 15'th Nov 2021 FinanzNachrichten
Mechelen, Belgium; 15 November 2021; 16.45 CET; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the European Commission has granted marketing authorization for Jyseleca (filgotinib 200m
Jyseleca®?(filgotinib) approved in the European Union for the treatment of ulcerative colitis
03:45pm, Monday, 15'th Nov 2021 Finanzen AT
Mechelen, Belgium; 15 November 2021; 16.45 CET; Galapagos NV (Euronext Nasdaq: GLPG) announced today that the European Commission has granted marketing authorization for Jyseleca ® (filgotinib 200mg tablets) for the treatment of adult patients with moderately to severely
Galapagos NV's (GLPG) CEO Onno van de Stolpe on Q3 2021 Results - Earnings Call Transcript
02:30pm, Friday, 05'th Nov 2021
Galapagos NV's (GLPG) CEO Onno van de Stolpe on Q3 2021 Results - Earnings Call Transcript
Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients
09:04am, Tuesday, 05'th Oct 2021
Galapagos NV (NASDAQ: GLPG) announced results of two post-hoc analyses from the SELECTION and SELECTION LTE studies of filgotinib for active ulcerative colitis (UC). The analyses showed clinical
Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease
07:08am, Monday, 04'th Oct 2021
Galapagos NV (NASDAQ: GLPG) has randomized the last patient into the DIVERSITY Phase 3 study of filgotinib in the induction and maintenance of remission in patients with Crohn's Disease (CD). The D
Galapagos Says New CEO Will Have Strong Science Background
05:30pm, Tuesday, 31'st Aug 2021
When any team underperforms, it's usually the manager or coach who gets the axe. The same often holds true in the corporate world.
Galapagos' Long-Serving CEO Onno Van De Stolpe To Exit After R&D Setbacks
09:03am, Tuesday, 31'st Aug 2021
After 22 years at the helm of Galapagos NV (NASDAQ: GLPG), chief executive Onno van de Stolpe has decided it is time to retire and hand the reins to new leadership. He will stay in his role until
